StreetInsider.com News Articles

Iovanace Biotherapeutics (IOVA) PT Raised to $10 at TD Cowen

Tue, 25 Aug 2026 07:38:14 -0400

TD Cowen analyst Nicholas Lorusso raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $10.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "We are updating our Amtagvi sales estimates post Q2 EPS with Q3 and Q4 Amtagvi sales of $95MM and $99MM, respectively. This suggests 64% Y/Y Q3 and 54% Y/Y Q4 growth, relatively in-line with the 68% Y/Y Q2 growth, but we note this may be conservative. We updated our 2026 total revenue estimate to $385MM, which is ahead of the prior $350-370MM guidance range given the impressive Q2 results."

Iovanace Biotherapeutics (IOVA) PT Raised to $10 at TD Cowen

Tue, 25 Aug 2026 07:38:14 -0400

TD Cowen analyst Nicholas Lorusso raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $10.00 (from $7.00) while maintaining a Buy rating.

TD Cowen Assumes Iovanace Biotherapeutics (IOVA) at Buy

Sat, 22 Aug 2026 07:55:40 -0400

TD Cowen analyst Nich assumes coverage on Iovanace Biotherapeutics (NASDAQ: IOVA) with a Buy rating and a price target of $7.00.

For an analyst ratings summary and ratings history on Iovanace Biotherapeutics click here. For more ratings news on Iovanace Biotherapeutics click here.

Shares of Iovanace Biotherapeutics closed at $8.29 yesterday.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 17:15:00 -0400

SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 17:15:00 -0400

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of

Iovanace Biotherapeutics (IOVA) PT Raised to $7 at UBS

Thu, 20 Aug 2026 06:03:51 -0400

UBS analyst David Dai raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $7.00 (from $4.00) while maintaining a Neutral rating.

The analyst comments "IOVA reported a beat quarter with $91M Amtagvi revenue (above $80M consensus/ UBSe) and $9M in Proleukin revenue (slightly above ~$8M cons/UBSe) (see our note). Management attributed the ~52% q/q Amtagvi growth to strong demand from marketing and physician education efforts, and improved authorized treatment center (ATC) performances across segments including contributions from recently activated ATCs. Gross margin improved to 56% (vs. 41% in 1Q26) linked to ongoing improvements in manufacturing efficiency and cost savings. We

Iovanace Biotherapeutics (IOVA) PT Raised to $7 at UBS

Thu, 20 Aug 2026 06:03:51 -0400

UBS analyst David Dai raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $7.00 (from $4.00) while maintaining a Neutral rating.

Iovanace Biotherapeutics (IOVA) PT Raised to $11 at Mizuho

Tue, 18 Aug 2026 06:36:24 -0400

Mizuho analyst Mara Goldstein raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $11.00 (from $10.00) while maintaining a Outperform rating.

Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 10 Filed by: Kirby Daniel Gordon

Wed, 12 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26914445.html

Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 10 Filed by: Kirby Daniel Gordon

Wed, 12 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26914445.html

Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 06 Filed by: Roche Corleen M.

Mon, 10 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260810/26899340.html

Form 4 IOVANCE BIOTHERAPEUTICS, For: Aug 06 Filed by: Roche Corleen M.

Mon, 10 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260810/26899340.html

Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260807/26888722.html

Form SCHEDULE 13G IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260807/26888722.html

Iovanace Biotherapeutics (IOVA) PT Raised to $8 at Citizens

Fri, 07 Aug 2026 08:13:05 -0400

Citizens analyst Reni J. Benjamin raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $8.00 (from $5.00) while maintaining a Market Outperform rating.

Iovanace Biotherapeutics (IOVA) PT Raised to $13 at Barclays

Fri, 07 Aug 2026 04:54:47 -0400

Barclays analyst Peter Lawson raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $13.00 (from $11.00) while maintaining a Overweight rating.

Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885725.html

Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 06

Thu, 06 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26885725.html

Why Investors Are Watching These Healthcare Movers

Thu, 06 Aug 2026 12:31:07 -0400

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ: CLRO), NeOnc Technologies (NASDAQ: NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.